Gynecologic Oncology

Ann Marie Beddoe, MD, discusses a study implementing cervical cancer screening and highlights HPV predictors in developing countries.

An immunotherapy targeting HPV-infected cells led to an unprecedented 1-year survival rate in patients with recurrent, metastatic cervical cancer.

A survey was given to parents of teenage girls in an effort to understand the relatively low uptake of the HPV vaccine in the United States.

Dmitriy Zamarin, MD, PhD, discusses the current state of immunotherapy in gynecologic cancers and necessary next steps for advancement in these diseases.

The University of Pennsylvania took a multidisciplinary team to Botswana to implement an approach to bring treatment to patients with cervical cancer in a more efficient and conducive way.

Ann H. Klopp, MD, PhD, discusses a phase III study highlighting the benefit of using intensity-modulated radiation therapy in gynecologic cancers and remaining challenges with radiation therapy in this setting.

A new study has provided yet more evidence that survivors of endometrial cancer should be closely monitored for cardiovascular disease.

Intentional weight loss in postmenopausal women has been found to be associated with a lower endometrial cancer risk, particularly among those with obesity, according to the results of a recent study published in the Journal of Clinical Oncology.

Anne Rositch, PhD, discusses important takeaways from her study on hysterectomy-corrected mortality rates in cervical cancer and the significance of cervical cancer screening.

Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses data from a trial comparing standard radiation therapy with intensity-modulated radiation therapy in patients with gynecologic malignancies.

Lois Ramondetta, MD, discusses the updated recommendations and the importance of advocating for lesser-known HPV-associated cancers.

Carolyn E. Banister, MD, discusses the results of a study that uncovered a new subtype of cervical cancer, as well as some of the remaining challenges in the overall treatment landscape.

A direct assessment of the uterine microbiome in patients with endometrial cancer has revealed a potential predictive role for vaginal microbes.

As mortality rates continue to climb in endometrial cancer, there remains a pressing need for effective screening and diagnostics.

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the prevalence of cervical cancer in the United States.

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the challenges associated with the patient demographics of cervical cancer.

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses patient preferences for cervical cancer treatment, as well as the demographics of this population.

The use of CT-planned high-dose-rate intracavitary brachytherapy demonstrated excellent local control and survival for patients with stage I/II cervical carcinoma, according to the results of a recent study published in Gynecologic Oncology.

Patients with endometrial cancer who receive surgery in the first 2 weeks after diagnosis have worse survival outcomes, according to a study recently reported in the American Journal of Obstetrics and Gynecology.

An association was found between the use of nonsteroidal anti-inflammatory drugs and endometrial cancer risk.

Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses the next steps to take with pelvic intensity-modulated radiation therapy for patients with gynecological cancers.

Dmitriy Zamarin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the novel approaches with immunotherapy that he would like to explore in the future treatment of patients with gynecologic cancers.

Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses the results of a study that compared the respective toxicities and quality of life outcomes associated with standard radiation and pelvic intensity-modulated radiation therapy for patients with various gynecologic malignancies.

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses some of the novel treatment options that could be explored in the future treatment of patients with cervical cancer.

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses some of the remaining challenges in treating patients with cervical cancer.